Australia's most trusted
source of pharma news
Posted 10 August 2022 AM
AbbVie has managed to keep the lion's share of the adalimumab market for Humira, despite biosimilars being available for more than a year now.
Pharma in Focus investigated the listings of adalimumab on the Federal Government's Medicare Statistics page, and found that for the first half of 2022, total pre-rebate reimbursement from the R/PBS for adalimumab was $139.3 million. Of that, a whopping $115.0 million was to reimburse Humira. That means AbbVie's originator brand still has 82.5 per cent of the market.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.